Showing results (241-250 of 317) with videos related to
Sort By:
Pageof 32
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2016
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progressionR Obermannová, E Van Cutsem, T Yoshino, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 24, 2023
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trialsJ Taieb, F A Sinicrope, L Pederson, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 4, 2016
The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, BarcelonaJ-L Van Laethem, F Carneiro, M Ducreux, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorinJ Cassidy, C Twelves, E Van Cutsem, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2014
Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013D Papamichael, R A Audisio, B Glimelius, et al.ESMO Open|June 2, 2022
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRCS Kopetz, A Grothey, E Van Cutsem, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2016
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinomaS-E Al-Batran, E Van Cutsem, S C Oh, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancerM Peeters, T J Price, A Cervantes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative GroupU Vanhoefer, P Rougier, H Wilke, et al.British Journal of Cancer|September 24, 2014
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL studyE Van Cutsem, C-P Li, E Nowara, et al.Pageof 32